- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 10.04. | "Resign or be fired" - APHA executive director calls out RFK Jr | ||
| 10.04. | AAN 2025: Long-term outcome data on steroid regimens in MG may guide treatment standards | ||
| 10.04. | PharmaLogic to boost radiopharma offerings with Agilera acquisition | ||
| 10.04. | FDA approves injectable antibiotics for B Braun drug delivery system | ||
| 09.04. | Merida launches with $121m to target autoimmune antibodies | ||
| 09.04. | IRA holds the scope to shape pharma's research strategy, say experts | ||
| 09.04. | Beyond oncology: The expanding potential of cell and gene therapies | ||
| 09.04. | 60 Degrees and Yale to progress tafenoquin for babesiosis | ||
| 09.04. | Pharma CEOs warn EC President of "risk of exodus" to US | ||
| 09.04. | Novo Nordisk outlays $1.09bn to boost GLP-1RA production in Brazil | ||
| 09.04. | US to impose tariffs on pharmaceutical imports | ||
| 09.04. | Obesity-related liver conditions: Understanding treatment options | ||
| 09.04. | AbbVie's upadacitinib gains EU marketing authorisation for GCA | ||
| 08.04. | Epsilogen acquires TigaTx to expand pan-isotope cancer antibody pipeline | ||
| 08.04. | KalVista licenses commercialisation rights for HAE to Kaken in Japan | ||
| 08.04. | UK Government to invest $764m into new health data service | ||
| 08.04. | EU president to meet pharma leaders as tariff threat looms | ||
| 08.04. | Ethris and Lonza to develop mRNA vaccines for respiratory conditions | ||
| 08.04. | Africa: The clinical impact of the US withdrawal from WHO and USAID | ||
| 08.04. | EC approves extension of indication for Janssen-Cilag's Darzalex | ||
| 08.04. | AD/PD 2025: Reporting of first real-world data for Leqembi focuses on operational challenges and safety | ||
| 07.04. | AD/PD 2025: First real-world data report for Leqembi focuses on operational challenges | ||
| 07.04. | China's NMPA authorises Santen's glaucoma treatment application | ||
| 07.04. | Obesity drugs won't be covered by Medicare under 2026 CMS policy | ||
| 07.04. | EC approves AstraZeneca's Imfinzi combo for NSCLC |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .